Rockwell Medical, Inc. announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. Dr. Lau has more than 20 years' experience in executive leadership of RD focused biopharma as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies.

Currently, Dr. Lau is CEO of Spirovant, where she is responsible for the strategic direction and growth of the gene therapy company. Previously, Dr. Lau co-founded and was Managing Partner of Militia Hill Ventures, which focuses on building and growing high quality life sciences companies. Dr. Lau led several biotech companies including Azelon Pharmaceuticals as President and CEO; Locus Pharmaceuticals and Immunome as COO.

Additionally, she served as a director of Renovacor until its acquisition by Rocket Pharmaceuticals and began her biopharmaceutical career at Merck Research Laboratories. Engaged in the Philadelphia community, Dr. Lau serves on the Boards of Trustees for the University of Pennsylvania, Brandywine Realty Trust, and the Philadelphia Orchestra. Dr. Lau earned a MBA from the Wharton School of Business and a BSE in Bioengineering, both at the University of Pennsylvania, and a Ph.D. in Neuroscience from the University of Cincinnati College of Medicine.